NorwayNorway

Risen from dead

06.03.2012

Bionor Pharma ASA’s development of an HIV vaccine is back on track. In mid-February, the Oslo-based company announced positive results from a Phase IIb study. When combined with antiretroviral treatment, the Vacc-4x vaccine knocked down the viral load in infected patients by 64%. Bionor had already lost hope for the vaccine, and its development was discontinued in 2010 after a previous study failed. Several weeks later, a US researcher reported that the vaccine triggered a plunge in viral load, and levels in patients did not swiftly climb when they were taken off of it. Those results revived Bionor’s hopes, and spurred the company to start the latest confirmatory trial. The positive news makes “a partnering process a natural next step” Bionor announced. The firm is now planning three different new studies for its vaccine.

NorwayNorway

10.06.2009

Oslo/Toulouse – The Norwegian Oslo Cancer Cluster and French Toulouse Cancer-Bio-Sante Cluster have announced they will be strengthening their collaboration. As a first step, the two are hosting a new conference to be held on...

NorwayNorway

07.06.2009

Oslo – Bjarte Reve, the CEO of the Oslo Cancer Cluster and also one of the 200 World Economic Forum’s 2009 Young Global Leaders, wants to use his new title to accelerate the development of better cancer diagnostics and treatments...

NorwayNorway

15.05.2009

Oslo – After assessing a variety of criteria, including efficacy in the prevention of cervical cancer, safety and evidence of long-lasting protection, Norwegian health authorities have chosen Sanofi Pasteur MSD’s Gardasil for the...

NorwayNorway

21.02.2009

Kalundborg – In January, Norwegian pharmaceutical company Pronova Bio-pharma ASA began recruiting employees for its new Danish plant, which is slated to go into operation within a year. In 2007, Pronova invested a200m in the port...

NorwayNorway

20.02.2009

Oslo – At the end of January, the Norwegian government put forward a biotech crisis package with a total volume of up to a150m. Key measures include an increased funding of innovation loans from the industrial development agency...

NorwayNorway

20.02.2009

Norwegian cancer therapeutics company Algeta ASA has announced plans to raise EUR27.7m (NOK 245m) through the private placement of 22.3 million new shares in a move managed by ABG Sundal Collier and DnB NOR Markets. Directed at...

NorwayNorway

21.01.2009

The Norwegian government is discussing a €300m rescue package for the biotech industry as part of a national financial rescue plan. The proposal for the plan was put forward by the academic institutes, hospitals and businesses...

NorwayNorway

19.08.2008

Oslo – Photocure ASA, one of the Norwegian biotech companies established around the Radium Hospital in Oslo, has finished its demerger and set up a new company named PCI Biotech. In June, the former subsidary raised EUR7.6m (NOK...

NorwayNorway

14.08.2008

Svalbard – During a two-day journey to the Arctic in June, German Research Minister Annette Schavan delivered 17,000 seed samples to the Norwegian Svalbard Global Seed Vault, which was opened in 2007. The samples were mainly...

NorwayNorway

14.08.2008

Oslo –Algeta A/S has started a Phase III study of its bone-targeting radium-223 drug Alpharadin that will enrol 750 men with advanced, hormone-refractory prostate cancer (HRPC). The primary efficacy endpoint of the trial is...

Displaying results 31 to 40 out of 92

< Previous 31-40 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-norway/browse/3/article/risen-from-dead.html

Print Magazine

Product of the week

Products

Events

All Events

Current issue

All issues